The study followed more than 1,400 participants over a 72-week treatment period and compared outcomes between the higher 7.2mg dose, the standard 2.4mg dose and placebo
Federal Programs May Expand Access, But Timeline Is Unclear The Trump administration announced the BALANCE model in December 2025, which aims to expand access to GLP-1s in Medicare and Medicaid by negotiating lower prices with manufacturers
Mean Changes in Anthropometry and Cardiometabolic Parameters at Week 68 in Study 6 in East-Asian Patients (WEGOVY 1.7 mg) Missing data were imputed from retrieved subjects of the same randomized treatment arm (RD-MI)
Because GLP-1s suppress appetites, WeightWatchers quickly learned that it needed an entirely new program for people taking the meds, said Gary Foster, the company's chief scientific officer
This cardiovascular benefit is now part of the FDA-approved indication for Wegovy
Our goal as a company is to become a proactive health and wellness platform and empowers people to get more insight into their wellness and to take action with personalized health programs. Compounded GLP-1 medication with limited name-brand medication availability MyStart is transparent about its GLP-1 medication costs and this is one of the first items it displays on its website
